1. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Issue 5 (May 2022) Authors: Nitz, Ulrike; Gluz, Oleg; Graeser, Monika; Christgen, Matthias; Kuemmel, Sherko; Grischke, Eva-Maria; Braun, Michael; Augustin, Doris; Potenberg, Jochem; Krauss, Katja; Schumacher, Claudia; Forstbauer, Helmut; Reimer, Toralf; Stefek, Andrea; Fischer, Hans Holger; Pelz, Enrico; zu Eulenburg, Chris... Journal: Lancet oncology Issue: Volume 23:Issue 5(2022) Page Start: 625 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. (November 2020) Authors: Nitz, Ulrike; Gluz, Oleg; Kreipe, Hans H.; Christgen, Matthias; Kuemmel, Sherko; Baehner, Frederick L.; Shak, Steven; Aktas, Bahriye; Braun, Michael; Lüdtke-Heckenkamp, Kerstin; Forstbauer, Helmut; Grischke, Eva-Maria; Nuding, Benno; Darsow, Maren; Schumacher, Claudia; Krauss, Katja; Malter, Wolf... Journal: Therapeutic advances in medical oncology Issue: Volume 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗